OrganOx Achieves One of the UK's Largest Medtech Exits to Date

OrganOx Achieves One of the UK’s Largest Medtech Exits to Date

OrganOx, an Oxford-based medtech firm known for its revolutionary liver perfusion technology improving transplant outcomes globally, has been acquired in a deal valued at about…

View More OrganOx Achieves One of the UK’s Largest Medtech Exits to Date
Paragraf Secures $55M in Series C Funding Round

Paragraf Secures $55M in Series C Funding Round

Paragraf, a UK company specializing in mass-producing graphene-based electronics using standard semiconductor processes, has completed a $55 million Series C funding round. This funding will…

View More Paragraf Secures $55M in Series C Funding Round
OrganOx of Oxford achieves one of the UK's largest MedTech exits with a $1.5 billion valuation

OrganOx of Oxford achieves one of the UK’s largest MedTech exits with a $1.5 billion valuation

OrganOx, a medical technology company based in Oxford, has been acquired for $1.5 billion. This acquisition marks one of the UK’s largest medtech exits, providing…

View More OrganOx of Oxford achieves one of the UK’s largest MedTech exits with a $1.5 billion valuation
Exploring the Future of Blockchain Technology: Recent Developments and Uses

Exploring the Future of Blockchain Technology: Recent Developments and Uses

Uncovering the Future of Blockchain Technology: Latest Updates and Applications Uncovering the Future of Blockchain Technology: Latest Updates and Applications Introduction to Blockchain Technology –…

View More Exploring the Future of Blockchain Technology: Recent Developments and Uses
Why Many AI Drug Discovery Startups Face Challenges — and How Turbine Intends to Succeed

Why Many AI Drug Discovery Startups Face Challenges — and How Turbine Intends to Succeed

Globally, significant resources and time are invested in researching new therapies that often fail clinically and benefit no patients. Envision a world where predicting a…

View More Why Many AI Drug Discovery Startups Face Challenges — and How Turbine Intends to Succeed
Chan Zuckerberg Initiative's rBio Trains AI Using Virtual Cells Instead of Lab Work

Chan Zuckerberg Initiative’s rBio Trains AI Using Virtual Cells Instead of Lab Work

The Chan Zuckerberg Initiative announced the launch of rBio, an artificial intelligence model designed to understand cellular biology through virtual simulations instead of expensive lab…

View More Chan Zuckerberg Initiative’s rBio Trains AI Using Virtual Cells Instead of Lab Work